Establishes an epinephrine auto-injector affordability program to provide low-cost epinephrine auto-injectors; requires insurance coverage for epinephrine auto-injectors and capping the co-pay or deductible for such at sixty dollars; makes failure to comply with the epinephrine auto-injectors affordability program a deceptive business practice; makes an appropriation therefor.
Requires health insurance plans to provide coverage for medically necessary epinephrine auto-injector devices; caps the out-of-pocket cost of the co-pay or deductible for such epi-pens at sixty dollars.
Requires health insurance plans to provide coverage for epinephrine auto-injector devices; caps the cost to an insured at $100 per year.
Requires health insurance plans to provide coverage for epinephrine auto-injector devices; caps the cost to an insured at $100 per year.
Provides for coverage of screenings for elevated lead levels exempting them from annual deductibles or coinsurance.
Relates to the substitution of brand name epinephrine auto-injectors with alternate epinephrine auto-injectors in certain cases.
Relates to the substitution of brand name epinephrine auto-injectors with alternate epinephrine auto-injectors in certain cases.
Requires schools to provide teachers with written informational material on the use of epinephrine auto-injectors.
Requires schools to provide teachers with written informational material on the use of epinephrine auto-injectors.
Provides public access to epinephrine auto-injector devices at schools; establishes public access epinephrine auto-injector device providers.